The 340B Drug Pricing Program “has enabled hospitals and health systems to support and expand access and services consistent with their mission and the program’s original and ongoing charge,” the AHA and Association of American Medical Colleges today told leaders of the House Energy and Commerce Committee and its Subcommittee on Oversight and Investigations. In the letter, AHA and AAMC provided examples of how hospitals and health systems have used 340B savings to expand access and services. These include supporting neonatal intensive care units and training for physicians to care for vulnerable newborns; providing low-income patients with free outpatient drugs; and pharmacist counseling services for medication therapy disease management, including telephone consultations for outpatients with conditions such as diabetes, hypertension and asthma. The letter also notes that the 340B program is not federally funded, and 340B sales are less than 3% of the total U.S. drug market. The Oversight and Investigations Subcommittee will hold a hearing on the 340B program Oct. 11.

Related News Articles

Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law…
Headline
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B…
Headline
The AHA May 8 filed an amicus brief in the U.S. District Court for the District of Nebraska in defense of the state’s 340B contract pharmacy law prohibiting…
Headline
Leaders from the Centers for Medicare & Medicaid Services at the 2025 AHA Annual Membership Meeting May 5 discussed issues on the agency’s agenda in a…